Principal Investigator
Sangeetha Venugopal
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20240189
Clinical Trial Summary
A Phase 1b Study of Menin Inhibitor SNDX-5613 in Combination with Daunorubicin and Cytarabine in Newly Diagnosed Patients with Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype with Higher-Risk Features or MLL/KMT2A Rearranged Disease.
Phase
Phase I
Funding Agency/Sponsor
National Cooperative Group
Disease
Leukemia
Contact Information
Phone Number
+1 (305) 2437261